Literature DB >> 21923181

Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.

Maria J Matos1, Carmen Terán, Yunierkis Pérez-Castillo, Eugenio Uriarte, Lourdes Santana, Dolores Viña.   

Abstract

New series of 6-substituted-3-arylcoumarins displaying several alkyl, hydroxyl, halogen, and alkoxy groups in the two benzene rings have been designed, synthesized, and evaluated in vitro as human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitors. Most of the studied compounds showed a high affinity and selectivity to the hMAO-B isoenzyme, with IC(50) values on nanomolar and picomolar range. Ten of the 22 described compounds displayed higher MAO-B inhibitory activity and selectivity than selegiline. Coumarin 7 is the most active compound of this series, being 64 times more active than selegiline and also showing the highest hMAO-B specificity. In addition, docking experiments were carried out on hMAO-A and h-MAO-B structures. This study provided new information about the enzyme-inhibitor interaction and the potential therapeutic application of this 3-arylcoumarin scaffold.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21923181     DOI: 10.1021/jm200716y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  In vitro evaluation of 3-arylcoumarin derivatives in A549 cell line.

Authors:  Musiliyu A Musa; Moise Y Joseph; Lekan M Latinwo; Veera Badisa; John S Cooperwood
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

Review 2.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

3.  MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study, and docking calculations.

Authors:  G L Delogu; F Pintus; L Mayán; M J Matos; S Vilar; J Munín; J A Fontenla; G Hripcsak; F Borges; D Viña
Journal:  Medchemcomm       Date:  2017-07-07       Impact factor: 3.597

4.  Antioxidant Activities of 4-Methylumbelliferone Derivatives.

Authors:  Yasameen K Al-Majedy; Ahmed A Al-Amiery; Abdul Amir H Kadhum; Abu Bakar Mohamad
Journal:  PLoS One       Date:  2016-05-31       Impact factor: 3.240

5.  Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.

Authors:  Maykel Cruz-Monteagudo; Fernanda Borges; M Natalia D S Cordeiro; Aliuska Morales Helguera; Eduardo Tejera; Cesar Paz-Y-Mino; Aminael Sanchez-Rodriguez; Yunier Perera-Sardina; Yunierkis Perez-Castillo
Journal:  Curr Neuropharmacol       Date:  2017-11-14       Impact factor: 7.363

6.  Mitigation of H(2)O(2)-Induced Mitochondrial-Mediated Apoptosis in NG108-15 Cells by Novel Mesuagenin C from Mesua kunstleri (King) Kosterm.

Authors:  Gomathi Chan; Muhamad Noor Alfarizal Kamarudin; Daniel Zin Hua Wong; Nor Hadiani Ismail; Faizuri Abdul Latif; Aurengzeb Hasan; Khalijah Awang; Habsah Abdul Kadir
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-17       Impact factor: 2.629

7.  3-Phenyl-coumarin.

Authors:  Maria J Matos; Lourdes Santana; Eugenio Uriarte
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-08-04

8.  N-(2-Oxo-2H-chromen-3-yl)cyclo-hexane-carboxamide.

Authors:  Maria J Matos; Lourdes Santana; Eugenio Uriarte
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-11-24

9.  3-(4-Meth-oxy-benzo-yl)-6-nitro-coumarin.

Authors:  Saleta Vazquez-Rodriguez; Eugenio Uriarte; Lourdes Santana
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-02-06

10.  Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors.

Authors:  Sanna Rauhamäki; Pekka A Postila; Sanna Niinivehmas; Sami Kortet; Emmi Schildt; Mira Pasanen; Elangovan Manivannan; Mira Ahinko; Pasi Koskimies; Niina Nyberg; Pasi Huuskonen; Elina Multamäki; Markku Pasanen; Risto O Juvonen; Hannu Raunio; Juhani Huuskonen; Olli T Pentikäinen
Journal:  Front Chem       Date:  2018-03-02       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.